Emerging treatments
Amniotic membrane transplantation
Ocular surface burns cause damage to limbal epithelial stem cells, leading to delayed re‐epithelialisation, stem cell failure, and conjunctivalisation. Although amniotic membrane transplantation (AMT) performed early (before day 7) has the potential to reduce pain and accelerate healing, a Cochrane review in 2020 concluded that it offered no significant benefit in the management of moderate or severe burns on several key outcomes (e.g., preventing failure of epithelialisation, improving visual outcome, reducing corneal neovascularisation or symblepharon formation, and time‐to‐epithelialisation).[70]
Dasatinib
Dasatinib (a multi-tyrosine kinase inhibitor) administered via intravitreal injection of either bolus solution or suspension in biodegradable nanoparticles on days 4 and 18 post-trauma may help to prevent early fibrotic changes following ocular trauma.[71]
Use of this content is subject to our disclaimer